普瑞玛尼(PA-824)用于结核病治疗的研究进展

宋凌云; 孙峰

doi:10.3969/j.issn.1673-6184.2023.03.007

微生物与感染 ›› 2023, Vol. 18 ›› Issue (3) : 171-175. DOI: 10.3969/j.issn.1673-6184.2023.03.007

综述

普瑞玛尼(PA-824)用于结核病治疗的研究进展

宋凌云，孙峰

作者信息 +

Advances in pretomanid for tuberculosis treatment

SONG Lingyun, SUN Feng

Author information +

文章历史 +

摘要

普瑞玛尼(PA-824)是最新批准用于结核病治疗的药物之一。药理学和临床研究表明，含有普瑞玛尼的治疗方案对药物敏感结核病和耐药结核病均有优异的杀菌活性和临床疗效，普瑞玛尼投入临床应用后有望为结核病治疗策略带来突破性的改变。本文综述了普瑞玛尼的药理学特性和现有临床研究，总结了其疗效和安全性

Abstract

Pretomanid (PA-824) is one of the latest drugs approved for the treatment of tuberculosis. Pharmacological and clinical studies have shown that regiments containing pretomanid have magnificent bactericidal activity and efficacy against drug-sensitive tuberculosis (Ds-TB) and drug-resistant tuberculosis (Dr-TB). It is expected that pretomanid will revolutionize tuberculosis treatment strategies when put into clinical practice. This article reviews the pharmacological characteristics and clinical studies of pretomanid, and summarizes its efficacy and safety.

导出引用

宋凌云，孙峰. 普瑞玛尼(PA-824)用于结核病治疗的研究进展[J]. 微生物与感染. 2023, 18(3): 171-175 https://doi.org/10.3969/j.issn.1673-6184.2023.03.007

SONG Lingyun, SUN Feng. Advances in pretomanid for tuberculosis treatment[J]. Journal of Microbes and Infections. 2023, 18(3): 171-175 https://doi.org/10.3969/j.issn.1673-6184.2023.03.007

中图分类号： R521 R978　